Clinical trial NCT03669614: SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
Official title: A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis
Gallium Citrate
Pseudomonas Aeruginosa
Lead sponsor: Aridis Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2018-09-13
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a dose-escalation, placebo-controlled study where subjects are randomized to receive study drug or placebo.

SAD and MAD HV Phases: The HV SAD and MAD will each include up to 24 adult subjects in 3 groups (8 per dose group) in each the SAD and MAD phase . All subjects will be randomly assigned in a 3:1 ratio to receive a single administration of active drug (12 HVs) or placebo (4 HVs).

The CF MAD will evaluate 4 different dose levels in a total of 54 adult CF subjects (10 per dose level). The first 3 subjects (sentinel subjects) in the low, medium and high dose level will be randomly assigned at a 2:1 ratio to receive either AR-501 or placebo, for a total of 9 CF subjects. An expanded cohort will randomize 30 adult subjects at a 2:3:3:2 ratio to three doses of inhaled AR-501 or placebo. Subsequently an 80mg Ga dose (top dose) cohort will randomize subjects at a 2:1 ratio to receive either AR 501 or placebo for a total of 15 subjects , including 6 sentinel subjects.
Primary purpose: TREATMENT

Brief summary: This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmacokinetic (PK) profile of single and repeat administrations of inhaled AR-501 solution in healthy adults, and the safety, PK and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF subjects.

Detailed description: Three dose levels (low, medium and high) will be assessed in succession, first in healthy volunteer (HV) subjects, then four ascending doses will be assessed in cystic fibrosis (CF) subjects. The study will be performed in 2 parts: Phase 1 part of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a part of the study in CF subjects will consist of a MAD study design.

The HV cohort will include up to 48 subjects. The CF cohort will have 54 subjects. Thus, the total number of subjects is 102.

The Phase 1 HV study will be performed at a Phase 1 Clinical Study Unit and the Phase 2a will be performed at approximately 24 clinical trial sites located in the United States and possibly in Europe, some of which may be part of the Cystic Fibrosis Foundation (CFF)-accredited Therapeutic Development Network (TDN) or the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN). Subjects who meet all eligibility criteria, including giving informed consent, will be enrolled and undergo a screening period of 28 days for HV cohorts and 42 days for CF Cohorts.

The HV cohort will include up to 24 adult subjects in 3 dose groups (8 per dose group \[Low, Medium and High\]) for the SAD phase of the study. In each dose group, subjects will be randomly assigned in a 3:1 ratio to the active drug or placebo, resulting in 6 subjects receiving inhaled AR-501 and 2 receiving inhaled placebo in a double-blind manner. The HV MAD phase of the study will include 24 adult subjects in 3 dose groups (8 per dose group \[Low, Medium and High\]). In each dose group, subjects will be randomly assigned in a 3:1 ratio to active study drug or placebo, resulting in 6 subjects receiving inhaled AR-501 and 2 receiving inhaled placebo in a double-blind manner. All subjects in HV MAD cohorts will receive once weekly inhaled study drug (either AR-501 or matching placebo) for 4 weeks for a total of 5 doses.

The CF MAD cohort will evaluate 4 different dose levels for a total of 54 adult CF. Of the 54 subjects, 40 will be randomized to receive one of the three ascending doses of AR-501, while 14 will be randomized to receive placebo. All subjects in CF cohorts will receive once weekly inhaled study drug (either AR-501 or matching placebo) for 2 weeks for a total of 3 doses.

The primary purpose of this study is to assess preliminary clinical safety of inhaled AR-501. The true frequency of AEs is unknown, and the sample size cannot be estimated accurately. For unknown AEs, the probabilities of observing at least 1 AE among 36 total healthy adult subjects and 40 adult CF subjects receiving any AR-501 dose are ≥ 80% if the true rate of such events are at least 4.4% and 4.8% respectively.

Eligibility criteria: Inclusion Criteria (HV Subjects):

1. Written informed consent given by the subject.
2. At least ≥ 18 years old and \< 50 years of age.
3. Healthy with no acute medical condition for ≥ 2 weeks prior to screening and no known chronic medical condition requiring regular medical follow up and care.
4. Body mass index (BMI) between 18 and 30 kg/m2, inclusive.
5. Currently nonsmoking and no history of using nicotine/tobacco-containing products for ≥ 5 years prior to screening.
6. Normal chest X-ray, per opinion of the Investigator.
7. FEV1 ≥ 80% of predicted values.
8. No history or current illicit, pharmaceutical drug or alcohol abuse within ≤ 5 years prior to screening.
9. A female subject must meet one of the following criteria:

   If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 90 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:
   * Abstinence from heterosexual intercourse
   * Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
   * Intrauterine device (with or without hormones), OR
   * Agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 90 days after the last dose of the study medication

   If a female of non-childbearing potential, the subject should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses), as confirmed by follicle stimulating hormone (FSH) levels.
10. A male subject must agree to use a double barrier method (e.g., condom and spermicide) during the study and for at least 90 days after the last dose of the study medication.

Inclusion Criteria (CF Subjects):

1. Written informed consent given by the subject.
2. At least18 years old
3. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

   * Sweat chloride equal to or greater than 60 mmol/liter by quantitative pilocarpine iontophoresis test (QPIT)
   * Two well-characterized, disease-causing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
4. Confirmation of current colonization/infection with P. aeruginosa defined as: a positive sputum or oropharyngeal swab culture at screening.
5. Respiratory symptoms and CF status are stable with no acute exacerbation at the time of randomization.
6. BMI ≥ 18 kg/m2
7. Currently non-smoking and no history of using nicotine/tobacco-containing products or smoking/vaping (inhaled tobacco products or other inhaled substances) for ≥ 1 year prior to screening.
8. FEV1 ≥ 45% of predicted values.
9. Serum creatinine and total bilirubin are both \< 1.5 x upper limit of normal (ULN) range (isolated bilirubin \> 1.5 x ULN range is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%).
10. A female subject must meet one of the following criteria:

    * If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 21 days prior to the first administration of the study medication, during the study, and for at least 28 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:

      * Abstinence from heterosexual intercourse
      * Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
      * Intrauterine device (with or without hormones), OR
      * Agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 28 days after the last dose of the study medication
    * If a female of non-childbearing potential, the subject should be surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels.
11. A male subject must agree to use a double barrier method (e.g., condom and spermicide) during the study and for at least 28 days after the last dose of the study medication.
12. Ability to produce an oropharyngeal sample (e.g., Expectorated Sputum or throat swab).

Exclusion Criteria (HV Subjects):

None of the following criteria can be met.

1. Female subjects who are currently pregnant or lactating.
2. Oral temperature above 37.5ºC at the time of screening or prior to randomization.
3. Clinically abnormal renal function, evidenced by serum creatinine \> 1.5 mg/dL.
4. Need for using any nephrotoxic agents during the study.
5. Known allergy or hypersensitivity to albuterol.
6. Significantly abnormal liver function:

   1. Total bilirubin \>1.5 x upper limit of the normal range (ULN),
   2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 3 x ULN and alkaline phosphatase (ALP) \> 2 x ULN
7. Hemoglobin \<10 g/dL
8. Abnormal corrected serum calcium concentration prior to enrollment.
9. History or current use of illicit, pharmaceutical drug or alcohol abuse within 5 years prior to screening.
10. Positive urine screen for alcohol, cotinine and/or drugs of abuse at screening and admission.
11. Positive test results for Human Immunodeficiency Virus (HIV)-1/HIV-2 antibodies, Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb).
12. Inability to comply with any study requirements based on judgement of the Investigator.
13. Any medical, psychological, cognitive, social or legal conditions that would interfere in the ability to give an informed consent and/or participate fully in the study.
14. Participation in another clinical trial involving receipt of an investigative product within 30 days before screening.
15. Any other reason as determined by an Investigator.

Exclusion Criteria (CF Subjects):

None of the following criteria can be met.

1. Female subjects who are currently pregnant or lactating.
2. Oral temperature above 37.5ºC (or temporal temperature above 38.0ºC) at the time of screening or prior to randomization.
3. Serum creatinine \> 1.5 mg/dL or known significant kidney disease.
4. Significantly abnormal liver function:

   1. Total bilirubin \> 1.5 x ULN range,
   2. ALT and/or AST \> 3 x ULN range and ALP \> 2 x ULN range.
5. History of medically attended hemoptysis \< 1 year (small amount of blood streaking in sputum is acceptable).
6. Pulmonary exacerbations within 3 months prior to randomization (defined as requiring IV antibiotics), in the hospital or at home.
7. Hemoglobin \< 10 g/dL.
8. Abnormal corrected serum calcium concentration prior to randomization (normal range is typically 8.5-10.2 mg/dL).
9. Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or CF-related conditions within 2 weeks prior to randomization.
10. Known allergy or hypersensitivity to albuterol or any component of the study drug or placebo
11. Use of illicit, pharmaceutical drug or alcohol abuse within 6 months prior to screening.
12. Positive urine screen for alcohol, cotinine and/or drugs of abuse at screening (positive results for a subject on Orkambi should have a confirmatory test for cannabinoids performed, e.g., reflex testing, to rule out cross reaction with Orkambi).
13. History of positive test result for human immunodeficiency virus (HIV) HIV-1/HIV-2 antibodies, HBsAg or chronic hepatitis C virus infection.
14. Inability to comply with any study requirements based on judgement of the Investigator.
15. Any medical, psychological, cognitive, social or legal conditions that would interfere in the ability to give an informed consent and/or participate fully in the study.
16. Participation in another clinical trial involving receipt of an investigative product within 30 days before randomization.
17. Suspected or confirmed acute respiratory infection (Examples: bacterial pneumonia, influenza, COVID-19).
18. Any other reason as determined by an Investigator.

Primary outcomes:
measure: Clinical safety profile (adverse events) - Single Ascending Dose
timeFrame: 28 days following dose administration
measure: Clinical safety profile (adverse events) - Multiple Ascending Dose
timeFrame: up to 28 days after last dose administration
Secondary outcomes:
measure: Pharmacokinetics (PK) Profile - SAD Cmax
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD Tmax
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD AUC0-inf
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD AUC0-last
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD λz
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD t½
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - SAD Clp
timeFrame: 28 days following dose administration
measure: Pharmacokinetics (PK) Profile - MAD Cmax
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD Tmax
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD AUC0-inf
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD AUC0-last
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD λz
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD t½
timeFrame: up to 28 days after last dose administration
measure: Pharmacokinetics (PK) Profile - MAD Clp
timeFrame: up to 28 days after last dose administration
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Research Site
state: Arizona
city: Long Beach
country: United States
facility: Research Site
state: California
city: Denver
country: United States
facility: Research Site
state: Colorado
city: Gainesville
country: United States
facility: Research Site
state: Florida
city: Hollywood
country: United States
facility: Research Site
state: Florida
city: Miami
country: United States
facility: Research Site
state: Florida
city: Orlando
country: United States
facility: Research Site
state: Florida
city: Tampa
country: United States
facility: Research Site
state: Florida
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: Iowa City
country: United States
facility: Research Site
state: Iowa
city: Overland Park
country: United States
facility: Research Site
state: Kansas
city: Louisville
country: United States
facility: Research Site
state: Kentucky
city: Portland
country: United States
facility: Research Site
state: Maine
city: Baltimore
country: United States
facility: Research Site
state: Maryland
city: Detroit
country: United States
facility: Research Site
state: Michigan
city: Omaha
country: United States
facility: Research Site
state: Nebraska
city: New York
country: United States
facility: Research Site
state: New York
city: Cleveland
country: United States
facility: Research Site
state: Ohio
city: Columbus
country: United States
facility: Research Site
state: Ohio
city: Oklahoma City
country: United States
facility: Research Site
state: Oklahoma
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Tyler
country: United States
facility: Research Site
state: Texas
city: Salt Lake City
country: United States
facility: Research Site
state: Utah
city: Seattle
country: United States
facility: Research Site
state: Washington
city: Spokane
country: United States
facility: Research Site
state: Washington
Study officials:
affiliation: Aridis Pharmaceuticals, Inc.
name: Hasan S Jafri, MD, FAAP
role: STUDY_DIRECTOR
affiliation: Aridis Pharmaceuticals, Inc.
name: Alan H Cohen, MD
role: STUDY_DIRECTOR
References: